IL239262A0 - Scanning methods - Google Patents

Scanning methods

Info

Publication number
IL239262A0
IL239262A0 IL239262A IL23926215A IL239262A0 IL 239262 A0 IL239262 A0 IL 239262A0 IL 239262 A IL239262 A IL 239262A IL 23926215 A IL23926215 A IL 23926215A IL 239262 A0 IL239262 A0 IL 239262A0
Authority
IL
Israel
Prior art keywords
screening
methods
Prior art date
Application number
IL239262A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of IL239262A0 publication Critical patent/IL239262A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
IL239262A 2012-12-10 2015-06-07 Scanning methods IL239262A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261735516P 2012-12-10 2012-12-10
US201361794685P 2013-03-15 2013-03-15
PCT/US2013/074218 WO2014093406A1 (en) 2012-12-10 2013-12-10 Methods for screening

Publications (1)

Publication Number Publication Date
IL239262A0 true IL239262A0 (en) 2015-07-30

Family

ID=49883268

Family Applications (2)

Application Number Title Priority Date Filing Date
IL239262A IL239262A0 (en) 2012-12-10 2015-06-07 Scanning methods
IL239261A IL239261A0 (en) 2012-12-10 2015-06-07 Lipoclin fusion partners

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL239261A IL239261A0 (en) 2012-12-10 2015-06-07 Lipoclin fusion partners

Country Status (11)

Country Link
US (4) US20140179560A1 (enExample)
EP (2) EP2928914A1 (enExample)
JP (2) JP2016505251A (enExample)
CN (2) CN105008393A (enExample)
AU (2) AU2013359429A1 (enExample)
BR (2) BR112015013515A2 (enExample)
CA (2) CA2913029A1 (enExample)
IL (2) IL239262A0 (enExample)
RU (2) RU2015126650A (enExample)
SG (2) SG11201504600UA (enExample)
WO (2) WO2014093406A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
SG11201504600UA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
ES3054697T3 (en) * 2013-09-17 2026-02-05 Blaze Bioscience Inc Chlorotoxin conjugates and methods of use thereof
KR101576904B1 (ko) 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
DK3298030T5 (en) * 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
AU2016283391A1 (en) * 2015-06-26 2017-11-30 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
EP3313427A4 (en) * 2015-06-26 2018-12-26 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
CA2994865A1 (en) * 2015-09-09 2017-03-16 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
JP7085990B2 (ja) * 2015-10-13 2022-06-17 シティ・オブ・ホープ クロロトキシンドメインを含むキメラ抗原レセプター
EP3373952A4 (en) * 2015-11-10 2019-05-22 Fred Hutchinson Cancer Research Center NKG2D decoys
CN105348392B (zh) * 2015-11-18 2019-08-02 北京华金瑞清生物医药技术有限公司 一种Nav1.7抑制剂及其改造方法
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
EP3442555A4 (en) * 2016-04-15 2020-04-01 Blaze Bioscience, Inc. METHOD FOR TREATING BREAST CANCER
US20190292243A1 (en) * 2016-08-22 2019-09-26 Fred Hutchinson Cancer Research Center Peptides and methods of use thereof
US11235076B2 (en) 2016-08-29 2022-02-01 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides
CN106699866A (zh) * 2016-12-13 2017-05-24 山西农业大学 一种鸡细胞外脂肪酸结合蛋白、原核表达及其纯化方法
CA3049262A1 (en) 2017-01-18 2018-07-26 Fred Hutchinson Cancer Research Center Peptide compositions and methods of use thereof for disrupting tead interactions
CN110475565A (zh) * 2017-03-16 2019-11-19 光明之火生物科学公司 软骨归巢肽缀合物及其使用方法
WO2018232122A1 (en) 2017-06-15 2018-12-20 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
CN107739410B (zh) * 2017-10-18 2021-07-30 南京鼓楼医院 CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用
JP7386161B2 (ja) 2017-12-19 2023-11-24 ブレイズ バイオサイエンス， インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
CA3093588A1 (en) * 2018-03-16 2019-09-19 Blaze Bioscience, Inc. Truncated cartilage-homing peptides and peptide complexes and methods of use thereof
US20230037660A1 (en) * 2019-12-19 2023-02-09 Blaze Bioscience, Inc. Methods of treating vascular lesions and malformations
CN115329965B (zh) * 2022-08-16 2025-08-01 北京有竹居网络技术有限公司 数据处理方法和电子设备
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3407582A1 (de) 1984-03-01 1985-09-05 Dornier System Gmbh, 7990 Friedrichshafen Schaltungsanordnung fuer einen regelkreis
WO1988002117A1 (en) 1986-09-19 1988-03-24 Scripps Clinic And Research Foundation Monoclonal paratopic molecule directed to human ganglioside gd2
US5591829A (en) 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5223253A (en) 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB2250993B (en) 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US5314992A (en) 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
EP0642353A1 (en) 1992-05-14 1995-03-15 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
IL108328A (en) 1993-01-14 2010-05-31 Cancer Res Campaign Tech Pharmaceutical compositions containing temozolomide and atase inhibitor for potentiation of temozolomide toxicity to human tumor cells
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US5756340A (en) 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
WO1997043301A2 (en) * 1996-05-10 1997-11-20 Novartis Ag Identification of members of combinatorial libraries by mass spectrometry
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
EP1055684A4 (en) 1997-12-05 2002-12-04 Kyogo Itoh TUMORANTIGENS IN THE FORM OF PEPTIDE DERIVATIVES
GB9809776D0 (en) * 1998-05-07 1998-07-08 Nycomed Imaging As Method
US6403625B1 (en) 1998-08-12 2002-06-11 Daiichi Pure Chemicals Co., Ltd. Fluorescent labeling reagents
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
ATE253126T1 (de) * 1998-08-25 2003-11-15 Univ Washington Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6629040B1 (en) * 1999-03-19 2003-09-30 University Of Washington Isotope distribution encoded tags for protein identification
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE10046508A1 (de) 1999-09-14 2001-04-05 Tridelta Bio Medical Gmbh Magnetische Nanoteilchen mit biochemischer Wikrsamkeit und Verfahren zu ihrer Herstellung sowie ihre Verwendung
AUPQ339899A0 (en) * 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
US6514481B1 (en) 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
DE10020376A1 (de) 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
US7229960B2 (en) 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20020077921A1 (en) 2000-12-15 2002-06-20 Paul-David Morrison Method and apparatus for an interactive catalog
WO2002069896A2 (en) 2001-03-01 2002-09-12 Northwest Hospital Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
GB0115581D0 (en) * 2001-06-26 2001-08-15 Glaxo Group Ltd Method of mass spectometry
US20030021810A1 (en) 2001-06-26 2003-01-30 Sontheimer Harald W. Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US6972326B2 (en) 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
WO2003066663A2 (en) 2002-02-04 2003-08-14 Auburn University Peptides for recognition and targeting of glial cell tumors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
CA2487425A1 (en) 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
US7563600B2 (en) * 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
EP1606399A4 (en) 2003-03-21 2006-08-02 Schering Corp METHOD OF SCREENING ON CELL QUALITY
CN1791671A (zh) * 2003-03-21 2006-06-21 先灵公司 靶配体的筛选方法
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DE10328251A1 (de) 2003-06-24 2005-01-13 Toximed Gmbh Pharmazeutischer Wirkstoff
US20070275902A1 (en) 2003-11-26 2007-11-29 Transmolecular, Inc. Treatment of Phosphatidylinositol Phospholipid Disorders
EP1544296B8 (fr) * 2003-12-18 2009-08-05 Biomethodes Procédé de mutagenèse dirigée massive
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
ATE459642T1 (de) 2004-04-06 2010-03-15 Transmolecular Inc Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
WO2006036928A2 (en) * 2004-09-27 2006-04-06 Wayne State University Inhibitors of matrix metalloproteinases to treat neurological disorders
GB0422901D0 (en) * 2004-10-14 2004-11-17 Ares Trading Sa Lipocalin protein
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
GB0504767D0 (en) * 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
US20060286089A1 (en) 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1877428B1 (en) 2005-04-22 2011-03-16 University of Washington Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
WO2007021297A1 (en) 2005-08-18 2007-02-22 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
CA2647907A1 (en) 2006-03-31 2007-10-18 Transmolecular, Inc. Use of tm-601 for the diagnosis and treatment of tumors
US8106013B2 (en) 2006-05-19 2012-01-31 Georgia Tech Research Corporation ABC transporter ligand GATX1
CN101003788A (zh) 2006-09-21 2007-07-25 武汉大学 一种蝎抗肿瘤转移肽及其制备方法和应用
CN100564517C (zh) 2006-09-21 2009-12-02 武汉大学 一种蝎抗神经胶质瘤肽及其制备方法和应用
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
US20090004105A1 (en) 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
EP2173385A1 (en) 2007-08-07 2010-04-14 Transmolecular, Inc. Chlorotoxins as drug carriers
US20110283260A1 (en) 2007-08-31 2011-11-17 Iosemantics, Llc Quality assurance tools for use with source code and a semantic model
CA2702314A1 (en) 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
EP2225268B1 (en) 2007-10-19 2012-08-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123970A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090176274A1 (en) 2007-10-19 2009-07-09 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
EP2215481B2 (en) 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
EP2244741B1 (en) 2008-01-18 2015-03-25 VisEn Medical, Inc. Fluorescent imaging agents
WO2009108762A2 (en) 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US8093060B2 (en) 2008-02-28 2012-01-10 Canon Kabushiki Kaisha Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same
EP3673922A1 (en) 2008-03-14 2020-07-01 VisEn Medical, Inc. Integrin targeting agents and methods of using same
US8470607B2 (en) 2008-03-20 2013-06-25 Morphotek, Inc. Inhibition of angiogenesis
GB0807831D0 (en) 2008-04-29 2008-06-04 Cambridge Entpr Ltd Agents for imaging cell death
CN101270158B (zh) 2008-04-30 2010-12-22 武汉大学 一种靶向抗神经胶质瘤蛋白及制备方法和用途
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
JP2009300110A (ja) 2008-06-10 2009-12-24 Olympus Corp 移植細胞の光学的検出方法又はイメージング方法
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
US20100098637A1 (en) 2008-09-23 2010-04-22 The Regents Of The University Of Michigan Dye-loaded nanoparticle
CN101381405B (zh) 2008-09-24 2011-07-27 武汉摩尔生物科技有限公司 基因工程肿瘤靶向kct-w1多肽及制备方法和用途
JP2010085108A (ja) 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
US20100331650A1 (en) * 2009-06-25 2010-12-30 Roche Diagnostics Operations, Inc. Episodic blood glucose monitoring system with an interactive graphical user interface and methods thereof
JP6059533B2 (ja) 2009-11-09 2017-01-11 ユニバーシティ オブ ワシントン センター フォー コマーシャライゼーション 官能化発色性ポリマードットおよびその生物共役体
CN101921769B (zh) 2010-01-11 2012-07-25 山西大学 一种重组腺病毒及其制备方法和应用
WO2011094671A2 (en) 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
JP5858932B2 (ja) 2010-02-04 2016-02-10 モルフォテック， インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
CN101824084A (zh) 2010-04-08 2010-09-08 山西大学 靶向性抗胶质瘤蛋白质及其应用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
AU2011290751B2 (en) * 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
CA2817197C (en) * 2010-11-08 2020-08-04 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2012092281A2 (en) 2010-12-28 2012-07-05 Quest Diagnostics Investments Incorporated Quantitation of insulin by mass spectrometry
DK2748357T3 (en) 2011-09-07 2018-07-16 X Chem Inc Methods for labeling DNA-encoded libraries
SG11201504600UA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening

Also Published As

Publication number Publication date
WO2014093406A1 (en) 2014-06-19
US20150322123A1 (en) 2015-11-12
US20150316536A1 (en) 2015-11-05
EP2928913A1 (en) 2015-10-14
BR112015013525A2 (pt) 2017-11-14
EP2928914A1 (en) 2015-10-14
US20140179560A1 (en) 2014-06-26
IL239261A0 (en) 2015-07-30
US10156559B2 (en) 2018-12-18
CN105189540A (zh) 2015-12-23
AU2013359426A2 (en) 2015-11-05
AU2013359429A1 (en) 2015-07-09
CA2913127A1 (en) 2014-06-19
BR112015013515A2 (pt) 2017-11-14
WO2014093403A1 (en) 2014-06-19
RU2015126651A (ru) 2017-01-16
AU2013359426A1 (en) 2015-07-09
RU2015126650A (ru) 2017-01-12
CA2913029A1 (en) 2014-06-19
SG11201504600UA (en) 2015-07-30
US20190101528A1 (en) 2019-04-04
SG11201504602VA (en) 2015-07-30
CN105008393A (zh) 2015-10-28
JP2016505826A (ja) 2016-02-25
AU2013359429A2 (en) 2015-11-12
JP2016505251A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
SG11201504600UA (en) Methods for screening
GB201217018D0 (en) Methods
IL235512A0 (en) New methods
ZA201501833B (en) Method for obtaining 1-kestone
IL237436A0 (en) A method for screening cancer
GB201212937D0 (en) Method
GB201212932D0 (en) Method
GB201213636D0 (en) Method
GB201212934D0 (en) Method
GB201210858D0 (en) Method
GB201208874D0 (en) Methods
GB2507760B (en) Methods
GB201120317D0 (en) Screening method
GB201202198D0 (en) Method
GB201214029D0 (en) method
GB201211393D0 (en) Method
GB201204280D0 (en) Methods
GB201213770D0 (en) Screening methods
GB201209689D0 (en) Methods
GB201208756D0 (en) Methods
GB201210147D0 (en) Method
GB201201332D0 (en) Method
PL2612712T3 (pl) Sito
GB201220686D0 (en) Methods
GB201208963D0 (en) Methods